日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer

患者来源的类器官可预测晚期卵巢癌对化疗和PARP抑制剂的反应

Wang, Haixia; Wang, Ling; Zhu, Xueping; He, Misi; Zhong, Lin; Lv, Yuyu; Li, Qiaoling; Jiang, Qinyue; Zhang, Cong; Liu, Xinghe; Zou, Dongling

Development and validation of deep learning for predicting the growth of ovarian cancer organoids

开发和验证用于预测卵巢癌类器官生长的深度学习方法

Wu, Hongji; Ma, Lifang; Wang, Ling; Zhu, Xueping; Luo, Xiaogang; Zhang, Cong; Ha, Chunfang; Dang, Yun; Wang, Haixia; Zou, Dongling

Risk factors associated with overall survival in patients with cervical cancer: a prospective cohort study in Western China comparing random survival forest and Cox proportional hazards models

宫颈癌患者总生存期相关危险因素:一项在中国西部开展的前瞻性队列研究,比较了随机生存森林模型和Cox比例风险模型

Mao, Zejia; Long, Ling; Yuan, Li; Xu, Qianjie; He, Misi; Lei, Haike; Zou, Dongling

A phase I dose-escalation study of Lobaplatin combined with paclitaxel in platinum-sensitive recurrent ovarian epithelial carcinoma: preliminary safety and tolerability supporting clinical trial dosing

洛铂联合紫杉醇治疗铂敏感复发性卵巢上皮癌的 I 期剂量递增研究:初步安全性和耐受性支持临床试验剂量

Zou, Dongling; Gong, Yi; Yang, Yingjie; Ma, Lifang; Yuan, Li; Bai, Jiaying; Zhou, Qi

A Chinese prospective cohort research developed and validated a risk prediction model for patients with cervical cancer

一项中国前瞻性队列研究建立并验证了一种宫颈癌患者风险预测模型。

Yuan, Li; Wen, Baogang; Li, Xiuying; Lei, Haike; Zou, Dongling; Zhou, Qi

The impact of preoperative immunonutritional status on prognosis in ovarian cancer: a multicenter real-world study

术前免疫营养状况对卵巢癌预后的影响:一项多中心真实世界研究

Liu, Xingyu; Li, Ming; Zhao, Yingjun; Jiao, Xiaofei; Yu, Yang; Li, Ruyuan; Zeng, Shaoqing; Chi, Jianhua; Ma, Guanchen; Huo, Yabing; Peng, Zikun; Liu, Jiahao; Zhou, Qi; Zou, Dongling; Wang, Li; Li, Qingshui; Wang, Jing; Yao, Shuzhong; Chen, Youguo; Ma, Ding; Hu, Ting; Gao, Qinglei

The impact of preoperative immunonutritional status on postoperative complications in ovarian cancer

术前免疫营养状况对卵巢癌术后并发症的影响

Liu, Xingyu; Li, Ming; Zhao, Yingjun; Jiao, Xiaofei; Yu, Yang; Li, Ruyuan; Zeng, Shaoqing; Chi, Jianhua; Ma, Guanchen; Huo, Yabing; Peng, Zikun; Liu, Jiahao; Zhou, Qi; Zou, Dongling; Wang, Li; Li, Qingshui; Wang, Jing; Yao, Shuzhong; Chen, Youguo; Ma, Ding; Hu, Ting; Gao, Qinglei

Dosimetric and clinical outcomes study of occult uterine tandem imperfect implantation in HDR-brachytherapy for cervical cancer

宫颈癌高剂量率近距离放射治疗中隐匿性子宫串联不完全植入的剂量学和临床结果研究

Zhao, Xiujuan; Wu, Haiyan; Yi, Ruotong; Chen, Duke; Tang, Ying; Zhou, Qi; Zou, Dongling

Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis

贝伐珠单抗联合化疗治疗PARP抑制剂治疗后复发的卵巢癌可能优于单纯化疗:一项多中心倾向评分匹配分析的证据

Zhong, Lin; Wang, Haixia; Lei, Cuirong; Zou, Dongling

Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines

推进对抗宫颈癌的斗争:治疗性HPV疫苗的前景

Zheng, Qian; He, Misi; Mao, Zejia; Huang, Yue; Li, Xiuying; Long, Ling; Guo, Mingfang; Zou, Dongling